These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6813991)

  • 1. Kinetics of the reaction between urokinase and an inhibitor of fibrinolysis from placental tissue.
    Christensen U; Holmberg L; Bladh B; Astedt B
    Thromb Haemost; 1982 Aug; 48(1):24-6. PubMed ID: 6813991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human articular cartilage contains an inhibitor of plasminogen activator.
    Yamada H; Stephens RW; Nakagawa T; McNicol D
    J Rheumatol; 1988 Jul; 15(7):1138-43. PubMed ID: 3139880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
    Aoki N; Moroi M; Matsuda M; Tachiya K
    J Clin Invest; 1977 Aug; 60(2):361-9. PubMed ID: 68962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator.
    Astedt B; Lecander I; Brodin T; Lundblad A; Löw K
    Thromb Haemost; 1985 Feb; 53(1):122-5. PubMed ID: 3922076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inhibitors of fibrinolysis with special reference to anti-t-PA (inhibitor of the tissue plasminogen activator)].
    Félez J; Rueda F
    Sangre (Barc); 1985; 30(4-C):779-86. PubMed ID: 3937250
    [No Abstract]   [Full Text] [Related]  

  • 6. Detection and partial characterization of a specific plasminogen activator inhibitor in human chondrocyte cultures.
    Yamada H; Stephens RW; Nakagawa T; McNicol D
    J Biochem; 1988 Dec; 104(6):960-7. PubMed ID: 3149640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purification of a plasminogen activator inhibitor indistinguishable from alpha1-antitrypsin and an urokinase inhibitor in pregnancy plasma.
    Clemmensen I; Thorsen S; Müllertz S
    Haemostasis; 1976; 5(4):218-30. PubMed ID: 826461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of the inhibition by plasminogen activator inhibitor 2 of urokinase isolated from human urine and recombinant microorganisms. Further evidence for correct tertiary structure of recombinant urokinase.
    Cramer J; Steffens G; Günzler WA; Hess V; Flohé L
    Arzneimittelforschung; 1988 Aug; 38(8):1196-8. PubMed ID: 3143371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a macrophage-derived plasminogen-activator inhibitor. Similarities with placental urokinase inhibitor.
    Chapman HA; Stone OL
    Biochem J; 1985 Aug; 230(1):109-16. PubMed ID: 2932100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of placental urokinase inhibitor in toxemia of pregnancy.
    Terao T; Kobayashi T
    Biol Res Pregnancy Perinatol; 1983; 4(4):145-51. PubMed ID: 6360225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasminogen activators and inhibitor type-1 in alveolar osteitis.
    Serratì S; Margheri F; Bruschi S; D'Alessio S; Pucci M; Fibbi G; Tonelli P; Del Rosso M
    Eur J Oral Sci; 2006 Dec; 114(6):500-3. PubMed ID: 17184232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
    Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
    J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purification and characterization of placental plasminogen activator (PPA).
    Kobayashi T; Terao T
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 May; 37(5):783-92. PubMed ID: 3923141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet release protein which inhibits plasminogen activators.
    Booth NA; Anderson JA; Bennett B
    J Clin Pathol; 1985 Jul; 38(7):825-30. PubMed ID: 3926830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Borrelia burgdorferi-bound fibrinolytic enzymes by alpha2-antiplasmin, PAI-1 and PAI-2.
    Perides G; Noring R; Klempner MS
    Biochem Biophys Res Commun; 1996 Feb; 219(3):690-5. PubMed ID: 8645243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human leucocyte urokinase inhibitor--purification, characterization and comparative studies against different plasminogen activators.
    Kopitar M; Rozman B; Babnik J; Turk V; Mullins DE; Wun TC
    Thromb Haemost; 1985 Dec; 54(4):750-5. PubMed ID: 3879018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for a specific inhibitor.
    Korninger C; Collen D
    Thromb Haemost; 1981 Oct; 46(3):662-5. PubMed ID: 6171907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor.
    Lecander I; Roblin R; Astedt B
    Br J Haematol; 1984 Jul; 57(3):407-12. PubMed ID: 6430331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation of peptides with anti-urokinase activity from the human placenta.
    Uszynski M
    Thromb Haemost; 1980 Feb; 42(5):1411-6. PubMed ID: 6768150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.